Gilead Sciences, Inc. (NASDAQ:GILD) CFO Sells $228,375.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Gilead Sciences Stock Down 0.8 %

Shares of GILD stock traded down $0.73 during mid-day trading on Thursday, reaching $91.65. 8,948,285 shares of the company’s stock traded hands, compared to its average volume of 6,722,391. The company’s 50-day moving average price is $91.97 and its 200-day moving average price is $83.76. The company has a market cap of $114.22 billion, a P/E ratio of 1,018.33, a P/E/G ratio of 1.27 and a beta of 0.18. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.29 earnings per share. On average, equities analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were given a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.36%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

Wall Street Analyst Weigh In

A number of research analysts recently commented on GILD shares. BMO Capital Markets increased their target price on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. The Goldman Sachs Group raised their price objective on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a report on Thursday, November 7th. Wells Fargo & Company boosted their target price on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Robert W. Baird lifted their price target on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Finally, Bank of America reaffirmed a “buy” rating and issued a $109.00 price objective on shares of Gilead Sciences in a research note on Tuesday, December 10th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $97.96.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. WINTON GROUP Ltd lifted its holdings in shares of Gilead Sciences by 52.9% during the second quarter. WINTON GROUP Ltd now owns 8,800 shares of the biopharmaceutical company’s stock valued at $604,000 after purchasing an additional 3,043 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Gilead Sciences by 0.6% in the second quarter. Massachusetts Financial Services Co. MA now owns 85,804 shares of the biopharmaceutical company’s stock worth $5,887,000 after acquiring an additional 522 shares during the period. One Capital Management LLC raised its holdings in shares of Gilead Sciences by 36.8% during the second quarter. One Capital Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $398,000 after purchasing an additional 1,560 shares during the last quarter. Citizens Financial Group Inc. RI lifted its position in Gilead Sciences by 36.1% during the second quarter. Citizens Financial Group Inc. RI now owns 5,984 shares of the biopharmaceutical company’s stock valued at $411,000 after purchasing an additional 1,588 shares during the period. Finally, Axxcess Wealth Management LLC boosted its holdings in Gilead Sciences by 10.2% in the second quarter. Axxcess Wealth Management LLC now owns 19,746 shares of the biopharmaceutical company’s stock worth $1,355,000 after purchasing an additional 1,830 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.